TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

Promotion of Jessica Morris

On January 4, 2018, the Board of Directors of Tonix Pharmaceuticals Holding Corp. (the “Company”) appointed Jessica Morris as the Company’s Chief Operating Officer.

Ms. Morris, age 39, has worked for the Company since April 2013, first as a consultant (April 2013 – September 2013), then as SVP of Finance (September 2013 – October 2015), followed by Chief Administrative Officer (October 2015 – January 2016), and Acting Chief Financial Officer (January 2016 – February 2016). She is currently Executive Vice President, Operations. Prior to joining the Company, Ms. Morris was a Vice President in investment management at Zhong Rong Group. Previously, Ms. Morris was a Senior Associate in the Sponsor Finance Group at American Capital, a Vice President of the mezzanine debt fund at Calvert Street Capital Partners, an Associate in the commercial finance department of Silicon Valley Bank, and a Financial Analyst in the investment banking group at Deutsche Bank. Ms. Morris earned a B.S. in Commerce and a B.A. in Music from the University of Virginia, where she was an Echols Scholar.

Item 8.01 Other Events.

On January 9, 2018, the Company issued a press release announcing Ms. Morris’ promotion, as discussed in Item 5.02 above. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.

The information contained in Item 8.01 of this Current Report on Form 8-K and Exhibit 99.01 are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

______

* Furnished herewith.


Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.01 2 s108674_ex99-01.htm EXHIBIT 99.01 Exhibit 99.01   Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer   NEW YORK,…
To view the full exhibit click here

An ad to help with our costs